[The future of antifungal agents].
Maesaki
Shigefumi
S
D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D004358:Drug Therapy / Q000639:trends*; D054714:Echinocandins; D006801:Humans; D017964:Itraconazole / Q000627:therapeutic use; D055666:Lipopeptides; D008074:Lipoproteins / Q000627:therapeutic use; D000077551:Micafungin; D009181:Mycoses / Q000188:drug therapy* / Q000517:prevention & control; D010456:Peptides, Cyclic / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D033581:Stem Cell Transplantation; D014230:Triazoles / Q000627:therapeutic use; D065819:Voriconazole
D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D008074:Lipoproteins; D010456:Peptides, Cyclic; D011743:Pyrimidines; D014230:Triazoles; C068538:liposomal amphotericin B; D017964:Itraconazole; D000666:Amphotericin B; D065819:Voriconazole; D000077551:Micafungin